Clinical benefit of measurement of remnant lipoprotein-cholesterol level in type 2 diabetes

Clinical benefit of measurement of remnant lipoprotein-cholesterol level in type 2 diabetes - Clinical benefit of RemL-C measurement in Type2 DM

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010436

Enrollment

200

Registered

2013-04-08

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We will recruited 200 patients with type 2 diabetes who were hospitalized for glycemic control in Kumamoto University Hospital.

Exclusion criteria

Exclusion criteria: 1. Patients with acute/chronic inflammatory disease 2. Patients with severe hepatic disease 3. Patients with fresh cerebrovascular disease 4. Patients with fresh cardiovascular disease 5. Patients with severe respiratory disease, heart disease and arrhythmia

Design outcomes

Primary

Measure	Time frame
Correlation between serum level of RemL-C and other atherosclerotic markers (leukocyte counts, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, fasting glucose level, fasting serum insulin level, HbA1c, hs-CRP, mean-IMT, baPWV, TNFalpha, IL-6, adiponectin, sd-LDL-C and hs-TnT).	—

Countries

Japan

Contacts

Public ContactTakeshi Matsumura

Faculty of life sciences, Kumamoto University Department of Metabolic Medicine

takeshim@gpo.kumamoto-u.ac.jp096-373-5169

Outcome results